,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2019-01-07 05:21:00,The year 2018 will certainly go down as the biggest in history for the marijuana industry .,0.1377648562192917,0.21996478736400604,0.6422703862190247,neutral,-0.08219993114471436
1,2019-01-07 05:21:00,"In October, Canada became the first industrialized country to legalize recreational cannabis.",0.5835382342338562,0.01281761284917593,0.4036441147327423,positive,0.5707206130027771
2,2019-01-07 05:21:00,"The following month, a handful of U.S. states legalized medical or adult-use weed.",0.055123720318078995,0.039424095302820206,0.9054521918296814,neutral,0.01569962501525879
3,2019-01-07 05:21:00,"Then, in December, a farm bill was signed into law that legalizes hemp and hemp-based cannabidiol in the United States.",0.5070637464523315,0.013489605858922005,0.4794466495513916,positive,0.4935741424560547
4,2019-01-07 05:21:00,"Then again, it was a pretty bad year overall for marijuana stock investors.",0.022740447893738747,0.9441447257995605,0.03311485797166824,negative,-0.9214043021202087
5,2019-01-07 05:21:00,"The most-followed cannabis exchange-traded fund was hammered, with more than 40% of all marijuana stocks with a market value in excess of $200 million losing at least 30% in 2018.",0.020596442744135857,0.9646709561347961,0.014732589945197105,negative,-0.9440745115280151
6,2019-01-07 05:21:00,"Mind you, this only includes pot stocks that were publicly listed as of Jan. 1, 2018, thereby excluding some highfliers, such as Tilray , that went public last year.",0.014388865791261196,0.01122263167053461,0.9743884801864624,neutral,0.0031662341207265854
7,2019-01-07 05:21:00,"These were the best-performing pot stocks in 2018

Of course, there were some marijuana stocks that bucked 2018's underperformance.",0.40676844120025635,0.1539662778377533,0.43926525115966797,neutral,0.25280216336250305
8,2019-01-07 05:21:00,"In total, four marijuana stocks more than doubled.",0.915582001209259,0.018630921840667725,0.06578707695007324,positive,0.8969510793685913
9,2019-01-07 05:21:00,"Perhaps most interesting, none of these marijuana stocks were on anyone's radar when the year began.",0.015304332599043846,0.022735808044672012,0.9619598388671875,neutral,-0.007431475445628166
10,2019-01-07 05:21:00,"Taking the crown as the marijuana stock of the year is small-cap CV Sciences (NASDAQOTH: CVSI) , which came really close to gaining 600%.",0.90690016746521,0.023362120613455772,0.06973769515752792,positive,0.8835380673408508
11,2019-01-07 05:21:00,"CV Sciences aims to develop novel therapeutics based on cannabidiol (CBD), the nonpsychoactive cannabinoid known for its perceived medical benefits.",0.32948482036590576,0.00839132908731699,0.6621238589286804,neutral,0.32109349966049194
12,2019-01-07 05:21:00,The company also retails hemp-based CBD products.,0.02695600315928459,0.005476825404912233,0.9675671458244324,neutral,0.021479178220033646
13,2019-01-07 05:21:00,The recent passage of the farm bill allowing hemp-based CBD to become legal should give CV Sciences and its products a much broader reach than in previous years.,0.8949363231658936,0.013120526447892189,0.0919431746006012,positive,0.8818157911300659
14,2019-01-07 05:21:00,"Through the first nine months of 2018, the company recorded $34 million in sales, a 153% year-over-year increase, with $7.1 million in net income.",0.9473603963851929,0.016431426629424095,0.0362081378698349,positive,0.9309289455413818
15,2019-01-07 05:21:00,"With profitability somewhat rare among pot stocks, CV Sciences has ridden the CBD wave to success.",0.9255911707878113,0.014193587936460972,0.06021524965763092,positive,0.9113975763320923
16,2019-01-07 05:21:00,"On the other hand, investors would be wise to tread cautiously around this stock.",0.22915679216384888,0.016818439587950706,0.7540248036384583,neutral,0.21233835816383362
17,2019-01-07 05:21:00,"Even though its retail business is doing fine, the company's cannabinoid-based drug development segment, which is working on a CBD-nicotine combo therapy as a smokeless tobacco-cessation solution, has faced attacks from noted short-seller Citron Research .",0.028133394196629524,0.9387578964233398,0.03310868889093399,negative,-0.9106245040893555
18,2019-01-07 05:21:00,"Citron claims that CV Sciences' CBD-nicotine therapy was rejected by the U.S. Patent and Trademark Office, yet that rejection was allegedly never disclosed to shareholders.",0.037724632769823074,0.7648254036903381,0.19745001196861267,negative,-0.7271007895469666
19,2019-01-07 05:21:00,The short-term losses in CV Sciences' stock following Citron's report have led to a slew of class action lawsuits on behalf of shareholders.,0.02509675733745098,0.9547889828681946,0.02011418715119362,negative,-0.9296922087669373
20,2019-01-07 05:21:00,"In other words, sustaining 2018's gains could prove difficult.",0.22193704545497894,0.6502957940101624,0.12776722013950348,negative,-0.4283587336540222
21,2019-01-07 05:21:00,"Even though cannabis consulting and grow-facility operator MariMed (NASDAQOTH: MRMD) wasn't the top-performing pot stock in 2018, its shareholders aren't going to complain about a 371% gain.",0.3670680820941925,0.5385016202926636,0.0944303348660469,negative,-0.17143353819847107
22,2019-01-07 05:21:00,MariMed predominantly made waves in 2018 with acquisitions and investments .,0.8505152463912964,0.011241140775382519,0.13824357092380524,positive,0.8392741084098816
23,2019-01-07 05:21:00,"In October, it closed on its acquisition of BSC Group in New Jersey.",0.02080862782895565,0.09290582686662674,0.8862856030464172,neutral,-0.07209719717502594
24,2019-01-07 05:21:00,"This could be a very smart purchase, with New Jersey looking like it is on the verge of legalizing recreational weed.",0.4549594223499298,0.02694586291909218,0.5180947780609131,neutral,0.42801356315612793
25,2019-01-07 05:21:00,BSC Group should be an immediate beneficiary of licensing and consulting within the cannabis industry if the New Jersey Legislature follows through and legalizes adult-use pot.,0.103563092648983,0.005660493858158588,0.8907763957977295,neutral,0.09790259599685669
26,2019-01-07 05:21:00,"MariMed also made an investment in Sprout, a company that makes software for customer relationship management (CRM) and marketing.",0.4914546012878418,0.009171857498586178,0.49937349557876587,neutral,0.48228275775909424
27,2019-01-07 05:21:00,"Considering that the marijuana industry has been dominated by cash, CRM software could prove pivotal to helping cannabis retailers better understand their customer base in the years to come.",0.8112992644309998,0.013075361959636211,0.17562533915042877,positive,0.7982239127159119
28,2019-01-07 05:21:00,"But as with CV Sciences, momentum could be tough to hang on to in 2019.",0.05321932211518288,0.4980049133300781,0.4487757682800293,negative,-0.44478559494018555
29,2019-01-07 05:21:00,"Despite 88% sales growth to $8.4 million through the first nine months of 2018, non-cash amortization pushed MariMed to an unsightly $18.2 million loss through Q3 2018.",0.020964616909623146,0.9626546502113342,0.0163807962089777,negative,-0.9416900277137756
30,2019-01-07 05:21:00,"Now that operating results actually matter, MariMed will have to do better to impress Wall Street.",0.8157233595848083,0.0333365835249424,0.15094003081321716,positive,0.7823867797851562
31,2019-01-07 05:21:00,Another under-the-radar pot stock that kicked tail and took names in 2018 is New Age Beverages (NASDAQ: NBEV) .,0.03905470296740532,0.019711725413799286,0.9412335753440857,neutral,0.019342977553606033
32,2019-01-07 05:21:00,"This definitely wasn't on marijuana stock investors' radars at the beginning of last year, because New Age didn't even announce its entrance into the cannabis industry until September.",0.01768156886100769,0.028344249352812767,0.953974187374115,neutral,-0.010662680491805077
33,2019-01-07 05:21:00,"Best known for its line of ready-to-drink coffees and teas, as well as kombucha, energy drinks, and relaxation beverages, New Age announced in mid-September that it would introduce a new line of CBD-based beverages at an October convenience-store trade show in Las Vegas.",0.32861724495887756,0.007700116373598576,0.6636826992034912,neutral,0.32091712951660156
34,2019-01-07 05:21:00,"The company wound up unveiling a CBD-infused sparkling water, a CBD-infused shot, and a CBD-infused tea.",0.3301721215248108,0.008624027483165264,0.6612038016319275,neutral,0.32154810428619385
35,2019-01-07 05:21:00,"With the Brightfield Group forecasting that CBD sales will explode from $591 million in 2018 to $22 billion by 2022, and two brand-name companies making infused-beverage deals with cannabis growers in August, investors piled into New Age Beverages on this announcement.",0.7789749503135681,0.037131600081920624,0.18389345705509186,positive,0.7418433427810669
36,2019-01-07 05:21:00,"Furthermore, five weeks ago, New Age announced its intent to acquire Morinda Holdings , which has about $240 million in annual sales and a distribution network that can reach 60 countries.",0.37592899799346924,0.007056375499814749,0.6170145869255066,neutral,0.36887261271476746
37,2019-01-07 05:21:00,This should allow New Age to utilize Morinda's distribution network to reach foreign countries with its CBD-based beverages.,0.9017786383628845,0.011261004023253918,0.08696043491363525,positive,0.8905176520347595
38,2019-01-07 05:21:00,"However (and I really don't mean to sound like a broken record), holding its 2018 gains won't be easy.",0.1770157516002655,0.26007530093193054,0.562908947467804,neutral,-0.08305954933166504
39,2019-01-07 05:21:00,"The introduction of CBD-based products should help sales in 2019, but the company's core products have pretty much fizzled out from a growth perspective.",0.11051488667726517,0.743022084236145,0.146463081240654,negative,-0.6325072050094604
40,2019-01-07 05:21:00,"Similarly, New Age doesn't look as if it'll turn a profit this year.",0.07404988259077072,0.07903315871953964,0.846916913986206,neutral,-0.004983276128768921
41,2019-01-07 05:21:00,"With CBD-infused beverages liable to be a competitive space, New Age could ultimately struggle.",0.10421450436115265,0.7696684002876282,0.12611709535121918,negative,-0.6654539108276367
42,2019-01-07 05:21:00,Vertically integrated grow-farm and dispensary operator iAnthus Capital Holdings (NASDAQOTH: ITHUF) saw its share price more than double in 2018.,0.9316731691360474,0.017601696774363518,0.05072522908449173,positive,0.9140715003013611
43,2019-01-07 05:21:00,Perhaps the biggest news for iAnthus last year was the October-announced $640 million deal to acquire MPX Bioceutical (NASDAQOTH: MPXEF) .,0.40345895290374756,0.023809103295207024,0.5727319717407227,neutral,0.3796498477458954
44,2019-01-07 05:21:00,"It remains the largest public-company-to-public-company acquisition in U.S. cannabis history, with MedMen Enterprises ' $682 million acquisition of privately held PharmaCann being the largest U.S. deal overall.",0.44075047969818115,0.009673030115664005,0.549576461315155,neutral,0.4310774505138397
45,2019-01-07 05:21:00,"When complete, the combination of iAnthus and MPX Bioceutical will have 56 retail stores and 14 cultivation and processing facilities across 10 states, with MPX bringing 10 dispensaries and six cultivation/processing facilities to the table.",0.291206419467926,0.006886952091008425,0.7019066214561462,neutral,0.2843194603919983
46,2019-01-07 05:21:00,"Among the 10 addressable states are California, which should become a larger market by annual sales than all of Canada; Florida, which is well on its way to $1 billion in annual sales; and New York, which appears likely to approve recreational pot in 2019.",0.5450312495231628,0.011971937492489815,0.4429967403411865,positive,0.533059298992157
47,2019-01-07 05:21:00,"As a refresher, no interstate transport of cannabis is allowed in the U.S., per federal law.",0.02560543641448021,0.10436626523733139,0.8700283765792847,neutral,-0.07876083254814148
48,2019-01-07 05:21:00,"This is why vertical integration is so important, and why the MPX Bioceutical deal makes sense.",0.21937502920627594,0.006946664769202471,0.7736782431602478,neutral,0.21242836117744446
49,2019-01-07 05:21:00,The big question in 2019 is whether iAnithus can generate an operating profit.,0.22707314789295197,0.018201308324933052,0.7547255158424377,neutral,0.20887184143066406
50,2019-01-07 05:21:00,"Unfortunately, with the vertically integrated dispensary model being very cost-heavy in the near term as companies seek to grab land and open stores, it's looking unlikely.",0.060674458742141724,0.27779629826545715,0.6615293025970459,neutral,-0.21712183952331543
51,2019-01-07 05:21:00,"10 stocks we like better than CV Sciences, Inc.",0.17445680499076843,0.016810506582260132,0.8087326884269714,neutral,0.1576462984085083
52,2019-01-07 05:21:00,"When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.12617750465869904,0.07430703938007355,0.799515426158905,neutral,0.05187046527862549
53,2019-01-07 05:21:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.",0.8087436556816101,0.0373060368001461,0.15395022928714752,positive,0.7714376449584961
54,2019-01-07 05:21:00,"*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and CV Sciences, Inc. wasn't one of them!",0.20581811666488647,0.015259945765137672,0.7789219617843628,neutral,0.19055816531181335
55,2019-01-07 05:21:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
56,2019-01-07 05:21:00,Click here to learn about these picks!,0.0694708302617073,0.055800698697566986,0.8747285008430481,neutral,0.01367013156414032
57,2019-01-07 05:21:00,Sean Williams has no position in any of the stocks mentioned.,0.009848862886428833,0.051502667367458344,0.938648521900177,neutral,-0.04165380448102951
58,2019-01-07 05:21:00,The Motley Fool has no position in any of the stocks mentioned.,0.011856832541525364,0.05262438580393791,0.9355188012123108,neutral,-0.04076755419373512
59,2019-01-07 05:21:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
60,2019-01-07 05:21:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
